FDA
Food and Drug Administration
Regulatory strategy for complex medical products
The science is complex. The path should be clear.
CERES transforms scientific evidence, regulatory expectations and program risk into a clear path forward.
What we solve
A regulatory partner for the moments that shape value.
Focused expertise, organized around the decisions development teams actually face—not an undifferentiated list of capabilities.
Regulatory strategy & health authority engagement
Development roadmaps, agency meeting strategy and clear positions that connect scientific evidence to regulatory expectations.
Advanced & innovative products
Specialized pathways for technologies where precedent is limited and cross-functional alignment is essential.
Evidence, clinical & CMC development
Integrated scientific and regulatory thinking across nonclinical, clinical, quality and manufacturing programs.
Regulatory rescue & fractional leadership
Senior intervention when a program has stalled, received difficult feedback or needs experienced leadership without a full-time hire.
How CERES works
From ambiguity to an executable path.
Every engagement begins by locating the decision that matters most. From there, evidence, risk and authority expectations are shaped into a practical program.
01
Frame the decision
Diagnose
Interrogate the evidence, history, assumptions and unresolved risk.
OutcomeA shared problem definitionEvidence map / gap register
02
Build the route
Design
Build a regulatory position and sequence the critical decisions.
OutcomeAn executable regulatory pathStrategy / decision sequence
03
Prepare the room
Align
Prepare the team and engage health authorities with clarity.
OutcomeOne defensible positionBriefing / authority engagement
04
Convert to action
Advance
Translate feedback into an accountable, executable program.
OutcomeDecisions moved into deliveryAction plan / ownership
“
Regulatory strategy is not a document. It is a sequence of decisions that protects the science, the timeline and the value of the program.
Selected public FDA approval timelines
Source references require client validation before publicationBLINCYTO®Breakthrough therapy2.5 months
ICLUSIG®Priority review2.6 months
SPINRAZA®Priority review3.0 months
Content retained from the current CERES website. Association and source attribution must be validated by CERES before production release.
Start with the consequential question
What is standing between your program and its next milestone?
Share the stage, the product and the decision ahead. CERES can help determine the right next conversation.
info@ceresregulatory.com